First Author: H.Kaldırım TURKEY
Co Author(s): K. Atalay
Back to previous
To evaluate functional and anatomical results of 0.7 mg single dose intravitreal dexamethasone implant (DEX; Ozurdex®, Allergan, Inc., Irvine, CA) in cystoid macular edema (CME) secondary to uneventful cataract surgery.
Bagcilar Training and Research Hospital
Fourteen eyes of the 14 patients with CME secondary to uneventful cataract surgery treated with 0.7 mg single dose intravitreal DEX implantation were reviewed in this retrospective study. Data including best corrected visual acuity measurements with Snellen charts (converted LogMAR), intraocular pressure (IOP) measurements with Goldman applanation tonometry, retinal examination, fluorescein angiography and macular thickness measurements obtained by a spectral domain optical coherence tomography (Spectralis OCT, Nidex RS 3000, in Japon) at baseline and 1., 10. day, 1, 3, and 6 months following Ozurdex® implantation was gained from files of the patients.
Fourteen eyes of the 14 patients (5 female, 9 male) with a mean age of 64.6 ± 10.9 years were treated with 0,7 mg intravitreal DEX implant injections. Visual acuity, CMT, and IOP were 0.50 ± 0.24 LogMAR, 528 ± 111 μm, and 14±1.2mmHg respectively prior to injection. One month after the injection mean CMT was decreased to 262 ± 40 μm, and visual acuity was increased to 0.10 ± 0.21 LogMAR. CMT and visual acuity measurements were stable in all patients at 3rd and 6th months. Mean IOP levels were increased from 13,2±1,8 mmHg to 17.2±5,6 mmHg in the first month. Only 3 patients required topical antiglaucomatous therapy at follow-up.
Our study showed that single-dose sustained-release dexamethasone implant (Ozurdex®) is an effective treatment option in patients having CME secondary to uneventful cataract surgery.